Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia

NCT ID: NCT02395081

Last Updated: 2021-03-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A double-blind randomized, placebo-controlled trial comparing the impact of 600 IU, 2000 IU, or 4000 IU of Vitamin D3 on third trimester 25(OH)D levels and change from baseline. The Vitamin D will be integrated in a standard prenatal vitamin, which will be taken from 12-16 weeks' gestation and continue throughout pregnancy. Umbilical cord 25(OH)D levels will also be determined. The investigators will generate preliminary data regarding Vitamin D intake and hypertensive disorders, blood pressure, and arterial function measured by tonography. The investigators will independently test blood pressure and proteinuria to identify preeclampsia cases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vitamin D deficiency (serum 25(OH)D levels \<20 ng/ml or 50 nmol/l) is widespread among Mongolians and is nearly universal during the winter months. The investigators have conducted a series of studies which have shown nearly universal Vitamin D deficiency in the winter months.

Observational studies in the U.S. have linked low 25(OH)D levels in women to a higher risk of preeclampsia. Mongolians also report levels of preeclampsia that are 3 times higher than those in the U.S (official reports cite 15%, though this may include gestational hypertension).

Given the widespread Vitamin D deficiency in Mongolian women, the high prevalence of hypertensive pregnancy in Mongolia, and the observational studies linking low 25(OH)D levels with preeclampsia risk, the investigators are conducting a pilot Vitamin D dosing trial to:

* Determine what level of Vitamin D supplementation is needed to secure 25(OH)D levels of at least 20 ng/ml in pregnant Mongolian women
* Generate preliminary data in support of a funding application for a larger trial of Vitamin D supplements to prevent preeclampsia in Mongolia

A double-blind randomized, placebo-controlled trial comparing the impact of 600 IU, 2000 IU, or 4000 IU of Vitamin D3 on third trimester 25(OH)D levels and change from baseline. The Vitamin D will be integrated in a standard prenatal vitamin, which will be taken from 12-16 weeks' gestation and continue throughout pregnancy. Umbilical cord 25(OH)D levels will also be determined. The investigators will generate preliminary data regarding Vitamin D intake and hypertensive disorders, blood pressure, and arterial function measured by tonography. The investigators will independently test blood pressure and proteinuria to identify preeclampsia cases.

The investigators will enroll 360 women who plan to receive their prenatal care and deliver at Zuun Kharaa Hospital in the Selenge province in northern Mongolia. Enrollment will be stratified by season. 120 women will be randomized to each of the three doses of vitamin D (600, 2000, 4000 IU) included in a standard prenatal vitamin.

Calcemia will be monitored two months after randomization and weeks 36-40 of pregnancy. Adverse events of pregnancy will be reported to the Data Safety and Monitoring Board (DSMB) and Institutional Review Board (IRB) per protocol.

Data will be gathered by a Mongolian study coordinator and local clinicians. A DSMB comprised of a U.S. and Mongolian clinicians and statisticians will monitor study data for safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

600 IU

Women will receive prenatal vitamins containing 600 IU of Vitamin D.

Group Type PLACEBO_COMPARATOR

600 IU Vitamin D3 in prenatal vitamin

Intervention Type DIETARY_SUPPLEMENT

Women will receive 600 IU 25(OH)D in prenatal vitamin.

2000 IU

Women will receive prenatal vitamins containing 2000 IU of Vitamin D.

Group Type EXPERIMENTAL

2000 IU Vitamin D3 in prenatal vitamin

Intervention Type DIETARY_SUPPLEMENT

Women will receive 2000 IU 25(OH)D in prenatal vitamin.

4000 IU

Women will receive prenatal vitamins containing 4000 IU of Vitamin D.

Group Type EXPERIMENTAL

4000 IU Vitamin D3 in prenatal vitamin

Intervention Type DIETARY_SUPPLEMENT

Women will receive 4000 IU 25(OH)D in prenatal vitamin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

600 IU Vitamin D3 in prenatal vitamin

Women will receive 600 IU 25(OH)D in prenatal vitamin.

Intervention Type DIETARY_SUPPLEMENT

2000 IU Vitamin D3 in prenatal vitamin

Women will receive 2000 IU 25(OH)D in prenatal vitamin.

Intervention Type DIETARY_SUPPLEMENT

4000 IU Vitamin D3 in prenatal vitamin

Women will receive 4000 IU 25(OH)D in prenatal vitamin.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* 12-16 weeks pregnant
* Receiving prenatal care at Zuun Kharaa Hospital and planning to deliver at Zuun Kharaa Hospital
* Willing not to take any additional vitamin D supplements, other than the study dispensed pills

Exclusion Criteria

* Existing known seizure disorder, renal failure, parathyroid disease, thyroid disease, sarcoidosis, cancer, or tuberculosis. (Tuberculosis is routinely screened in pregnancy)
* History of kidney stones
* Known sensitivity to multivitamin preparations
* Taking vitamin D supplements containing \>600 IU/day.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Center for Maternal and Child Health Research, Mongolia

UNKNOWN

Sponsor Role collaborator

Zuun Kharaa Hospital

OTHER

Sponsor Role collaborator

Brigham and Women's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Janet Rich-Edwards

Director of Developmental Epidemiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janet Rich-Edwards, ScD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zuun Kharaa Hospital

Selenge, Selenge Province, Mongolia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mongolia

References

Explore related publications, articles, or registry entries linked to this study.

Enkhmaa D, Tanz L, Ganmaa D, Enkhtur S, Oyun-Erdene B, Stuart J, Chen G, Carr A, Seely EW, Fitzmaurice G, Buyandelger Y, Sarantsetseg B, Gantsetseg G, Rich-Edwards J. Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women. EBioMedicine. 2019 Jan;39:510-519. doi: 10.1016/j.ebiom.2018.11.060. Epub 2018 Dec 11.

Reference Type DERIVED
PMID: 30552064 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14-0591-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitamin D in Pregnancy
NCT04291313 UNKNOWN NA
Vitamin D and Hypertensive Disorders of Pregnancy
NCT07017920 NOT_YET_RECRUITING NA
Bone and Muscle Health in Kids
NCT03537443 COMPLETED NA
Vitamin D During Pregnancy
NCT01589783 COMPLETED